Mr. Orevillo has over 25 years of experience in pharmaceutical clinical development and operations. Prior to joining Longboard, Mr. Orevillo served as the Vice President and Head of Clinical Operations of Arena Pharmaceuticals from April 2017 to March 2020. Prior to Arena, Mr. Orevillo served as the Vice President, Head of Clinical Development and Medical Communications and the Head of Clinical Operations at Pearl Therapeutics, Inc., a venture-funded biotech subsequently acquired and operated as a subsidiary of AstraZeneca since 2013. Mr. Orevillo joined Pearl in 2008 and was responsible for building and leading the clinical development and operations teams which were responsible for the Bevespi and Breztri Aerosphere development programs. Previously, Mr. Orevillo worked in various clinical development and operations roles at Novartis from 2003 to 2008, Pharmacia/Pfizer from 2000 to 2003, Merck from 1995 to 2000 and Pharmaco-LSR from 1993 to 1995. Mr. Orevillo has an M.P.H. from Tulane University and B.S. from William Paterson University. He is a US Marine Corps veteran of Operation Desert Storm.